Press release
Chronic Hepatitis B Virus Pipeline: 50+ Companies Driving Next-Generation Therapies and Disease Management | DelveInsight
Chronic Hepatitis B Virus Pipeline
DelveInsight's "Chronic Hepatitis B Virus - Pipeline Insight, 2025" offers an in-depth analysis of the current clinical development pipeline, encompassing investigational drugs from early discovery to late-stage clinical trials. This comprehensive report examines mechanisms of action targeting viral replication, cccDNA elimination, and immune system restoration, as well as therapeutic modalities including small molecules, therapeutic vaccines, and RNA interference agents.
Providing a 360° perspective, the report details drug profiles, clinical trial phases, delivery routes, and expected timelines for regulatory approval and market launch. It also highlights unmet medical needs, strategic collaborations, regulatory milestones such as fast-track and orphan designations, and evolving market dynamics that are set to transform the management and prognosis of Chronic Hepatitis B infection.
Interested in learning more about the current treatment landscape and the key drivers shaping the chronic hepatitis B virus pipeline? Click here: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report
• DelveInsight's chronic hepatitis B virus pipeline analysis depicts a strong space with 50+ active players working to develop 55+ pipeline drugs for Chronic Hepatitis B Virus treatment.
• The leading chronic hepatitis B virus companies include Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and others are evaluating their lead assets to improve the chronic hepatitis B virus treatment landscape.
• Key chronic hepatitis B virus pipeline therapies in various stages of development include Pradefovir, DA 2802, VIR-2218, AB-729, Selgantolimod, ATI-2173, ASC42, Hepalatide, QL-007, Antroquinonol, HEC121120, APG-1387, GSK3228836, JNJ-73763989, JNJ-56136379, Vonafexor, T101, BRII-179, aVTP-300, PA1010, P1101, NCO-48, HRS5091, EDP-514, CKD-388, LP-128, VNRX 9945, ZM-H1505R, ISA104, RG6346, HepTcell, RO7049389, RO7020531, and others.
• In April 2025, Precision BioSciences (Nasdaq: DTIL) announced that the FDA granted Fast Track designation to PBGENE-HBV, its lead in vivo gene editing therapy aimed at curing chronic hepatitis B by eliminating cccDNA and inactivating integrated HBV DNA.
• In March 2025, Precision BioSciences announced FDA clearance of its IND application for PBGENE-HBV, a meganuclease-edited in vivo therapy aimed at curing chronic hepatitis B.
• In January 2025, Bluejay Therapeutics, a clinical-stage biopharmaceutical company, announced that its lead drug candidate, brelovitug (BJT-778), received Breakthrough Therapy Designation from the US FDA. Brelovitug targets chronic hepatitis delta (CHD), a serious viral liver disease.
• In December 2024, Vir Biotechnology, Inc. announced that tobevibart and elebsiran received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for the treatment of chronic hepatitis delta (CHD).
Request a sample and discover the recent breakthroughs happening in the chronic hepatitis B virus pipeline landscape @ https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Hepatitis B Virus Overview
Hepatitis B virus (HBV) infection is a serious global health issue, causing potentially life-threatening liver disease. It spreads primarily through contact with infected body fluids such as blood, semen, and vaginal secretions. While over 95% of healthy adults can naturally clear the virus, infection may range from acute symptomatic illness to an asymptomatic state detected during routine screening. Clinical symptoms vary widely: acute infection can present as mild or severe hepatitis, including rare cases of fulminant hepatitis, while chronic infection may lead to an asymptomatic carrier state, ongoing liver inflammation, cirrhosis, or liver cancer. Transmission occurs through percutaneous exposure or mucosal contact with infectious fluids.
Find out more about chronic hepatitis B virus medication @ https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Hepatitis B Virus Treatment Analysis: Drug Profile
Pradefovir: Ligand Pharmaceuticals
Pradefovir is an oral prodrug that targets the liver and converts into adefovir, an HBV DNA polymerase/reverse transcriptase inhibitor. It is being developed using Ligand's HepDirect technology and is currently in Phase III trials for treating chronic hepatitis B.
RG6346: Dicerna Pharmaceuticals
RG6346 is an investigational GalXCTM RNA interference (RNAi) therapy being developed in collaboration with Roche for chronic HBV infection. It works by selectively silencing genes responsible for HBV mRNA production and viral entry into liver cells. Preclinical studies showed over 99.9% reduction in circulating HBsAg in mouse models. Unlike existing treatments that mainly suppress the virus, RG6346 aims to provide a functional cure. It is currently in Phase II clinical trials in adults with chronic HBV.
Learn more about the novel and emerging chronic hepatitis B virus pipeline therapies @ https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Hepatitis B Virus Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Chronic Hepatitis B Virus Pipeline Report
• Coverage: Global
• Key Chronic Hepatitis B Virus Companies: Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and others.
• Key Chronic Hepatitis B Virus Pipeline Therapies: Pradefovir, DA 2802, VIR-2218, AB-729, Selgantolimod, ATI-2173, ASC42, Hepalatide, QL-007, Antroquinonol, HEC121120, APG-1387, GSK3228836, JNJ-73763989, JNJ-56136379, Vonafexor, T101, BRII-179, aVTP-300, PA1010, P1101, NCO-48, HRS5091, EDP-514, CKD-388, LP-128, VNRX 9945, ZM-H1505R, ISA104, RG6346, HepTcell, RO7049389, RO7020531, and others.
Dive deep into rich insights for drugs used for chronic hepatitis B virus treatment; visit @ https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Hepatitis B Virus Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chronic Hepatitis B Virus Pipeline Therapeutics
6. Chronic Hepatitis B Virus Pipeline: Late-Stage Products (Phase III)
7. Chronic Hepatitis B Virus Pipeline: Mid-Stage Products (Phase II)
8. Chronic Hepatitis B Virus Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B Virus Pipeline: 50+ Companies Driving Next-Generation Therapies and Disease Management | DelveInsight here
News-ID: 4026593 • Views: …
More Releases from DelveInsight
Type 2 Diabetes Pipeline Insight 2025: Next-Gen Incretins, Gene Therapies, and M …
DelveInsight's "Type 2 Diabetes - Pipeline Insight, 2025" explores the evolving pipeline for type 2 diabetes (T2D), a chronic disorder marked by insulin resistance and progressive β-cell dysfunction. Despite widely used options like metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin, the global burden of T2D continues to rise, creating demand for therapies that go beyond glucose control to address weight, cardiovascular risk, and long-term disease modification.
The pipeline is advancing…
Wet Age-Related Macular Degeneration Pipeline Insight 2025: Over 60+ Companies A …
DelveInsight's "Wet-AMD - Pipeline Insight, 2025" maps a fast-moving landscape for neovascular (wet) age-related macular degeneration, a leading cause of vision loss driven by choroidal neovascularization and exudation. Today's standard of care relies on frequent intravitreal anti-VEGF injections, which are highly effective but create a heavy treatment burden and adherence challenges.
The pipeline is shifting toward durability and disease modification. Next-gen biologics (long-acting antibodies, bispecifics, and high-affinity fragments), small-molecule TKIs in…
Pulmonary Embolism Pipeline Insight 2025: Novel Anticoagulants, Thrombolytics, a …
DelveInsight's "Pulmonary Embolism - Pipeline Insight, 2025" explores the advancing treatment landscape for pulmonary embolism, a life-threatening condition resulting from obstruction of the pulmonary arteries, most often due to venous thromboembolism. Current management primarily relies on anticoagulation with heparins, vitamin K antagonists, or direct oral anticoagulants, and in severe cases, systemic thrombolysis or catheter-directed interventions. While these approaches improve survival, they are limited by bleeding risks, suboptimal clot resolution, and…
Immune Thrombocytopenia Clinical Trials 2025: Advancing TPO-R Agonists, FcRn Blo …
DelveInsight's "Immune Thrombocytopenia (ITP) - Pipeline Insight, 2025" highlights the rapidly evolving therapeutic landscape for ITP, an autoimmune bleeding disorder characterized by accelerated platelet destruction and impaired platelet production. Current treatments, such as corticosteroids, intravenous immunoglobulin (IVIG), rituximab, and thrombopoietin receptor (TPO-R) agonists like eltrombopag and romiplostim, provide effective short-term control for many patients, but relapses, refractoriness, and treatment-related toxicity remain significant challenges.
The pipeline is shifting toward therapies that deliver…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
